Summary
Second Generation Antipsychotics (SGAs) continue to drive the antipsychotic market with a growth rate of 27.2% between 2002-2003, yielding revenues of over $9.5 billion in 2003 responsible for a 93.3% share of the market. However, several patent expiries and product launches are set to send the market through a period of change.
With an increasingly crowded schizophrenia market, SGA manufacturers are seeking to add new indications to their product's labeling, capitalizing on the existing high off-label. Already, the majority of SGAs are approved for bipolar mania, and many have or are in the process of gaining approval for bipolar maintenance, as well as other niche areas.
Zyprexa, the market leading SGA, is currently experiencing patent challenges from numerous generics manufacturers. Datamonitor believes it is likely that Lilly will prevail in the courts, although, if generic incursion occurs in 2005, the SGA market could look very different.
The extreme interest in this market place by generics manufacturers is unsurprising. The SGA market currently includes three blockbuster brands with Abilify joining this select club in 2005. Datamonitor forecasts that three of the generic molecules will see blockbuster revenues by 2013.
This Report Includes:
- Overview of current market including profiles of key brands and key events impacting each brand during 2003-2004h3>
- Assessment of current and future opportunities and threats in the antipsychotics market across the seven major pharmaceutical markets
- Global sales for leading antipsychotic products from 1999-2003 are presented, with projections for future performance up to 2014h3>
- In-depth discussion of assumptions and events used in forecast analysis
|
